Precipio Inc (PRPO)
NASDAQ:PRPO
Want to see PRPO full AI Analyst Report?
Earnings Data
Report Date
May 20, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.59Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicates a generally positive trajectory: the company reached a key inflection to positive cash flow, delivered 30% revenue growth to $24M, improved overall gross margin from 41% to 45%, strengthened the commercial organization, and demonstrated product manufacturing scalability and clinical validation. Key challenges remain in the Products division—revenue growth was muted by customer operational interruptions, earlier under-resourced commercial coverage, onboarding timing and margin volatility driven by one-time production effects. Management presented concrete mitigations (new hires, backup lab arrangements, distributor strategy) and a clear growth focus for 2026, so the balance of developments is favorable but with identifiable execution risks to monitor.Company Guidance
Revenue Growth and Scale
Fiscal year 2025 revenue of $24.0M, representing +30% year-over-year growth, driven primarily by Pathology Services and increased demand for specialized diagnostic and molecular testing.
Positive Cash Flow and Balance Sheet Cleanup
Company achieved the strategic inflection to positive cash flow in 2025; exercised all remaining financial warrants and completed repayment of the Change Healthcare loan, moving toward a cleaner balance sheet.
Gross Margin Improvement
Overall gross margin improved from 41% in 2024 to 45% in 2025 (+4 percentage points), driven by higher case volumes, favorable case mix and improved operational efficiency in Pathology Services.
Pathology Services: Organic Growth and Operational Leverage
Pathology Services showed strong organic growth via new customer acquisition and increased volume from existing customers; laboratory infrastructure remains under capacity so incremental volume contributes disproportionately to margins and cash generation.
Products Manufacturing Scalability Demonstrated (Q4 Margin Spike)
Products division experienced an unusual Q4 product gross margin of 90% (versus ~30% in Q3 and historical ~40–50%) due to a concentrated production run to prebuild inventory for anticipated Q1 downtime — illustrating manufacturing scalability and potential high-margin profile as volumes scale.
Commercial Team Strengthened
Invested in commercial capabilities: in January 2026 hired an experienced Chief Commercial Officer plus two seasoned full-time business development professionals, expanding from ~1 part-time resource to 3 dedicated, experienced sales staff to accelerate product adoption.
Clinical & Academic Validation and Thought Leadership
Published a joint academic study with Memorial Sloan Kettering demonstrating clinical value of Bloodhound BCR-ABL; presented a poster at AMP with Wayne State University on the HemeScreen panel — bolstering clinical credibility.
Increased Market Engagement and Share Price Momentum
Management engaged publicly in 2025 with 50+ investor interactions; company reported ~300% share price appreciation during the year (management attributes appreciation to business and market engagement).
Strategic Product-Service Opportunities
Announced plan to launch next-day rapid molecular AML testing service (next-day results with comprehensive 5-day follow-up) leveraging both Pathology Services and Products to address an estimated $500M U.S. addressable market and shorten critical turnaround times.
PRPO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRPO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 06, 2026 | $25.40 | $25.98 | +2.28% |
Nov 14, 2025 | $19.33 | $21.03 | +8.79% |
Aug 13, 2025 | $14.29 | $14.71 | +2.94% |
May 14, 2025 | $6.93 | $7.15 | +3.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Precipio Inc (PRPO) report earnings?
Precipio Inc (PRPO) is schdueled to report earning on May 20, 2026, TBA (Confirmed).
What is Precipio Inc (PRPO) earnings time?
Precipio Inc (PRPO) earnings time is at May 20, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRPO EPS forecast?
Currently, no data Available